Explore

Rapid ReadRapid Read
Alamar Biosciences and Nightingale Health Partner with UK Biobank to Identify Early Biomarkers for Neurodegenerative Diseases

Alamar Biosciences and Nightingale Health Partner with UK Biobank to Identify Early Biomarkers for Neurodegenerative Diseases

Alamar Biosciences and Nightingale Health have initiated a collaborative study with the UK Biobank to identify early blood biomarkers for neurodegenerative conditions, including Parkinson’s and Alzheimer’s disease. This project, named UK Biobank Proteomics for Risk Identification and Signatures of brain health in Midlife, will analyze hundreds of proteins in 80,000 blood samples from UK Biobank participants. The study combines Alamar’s NULISA protein-detection technology, which can detect proteins at very low concentrations using antibodies and DNA-based signals, with Nightingale’s laboratory infrastructure and the UK Biobank’s extensive health data. The goal is to uncover early molecular signatures that could aid in predicting disease risk, improving diagnosis, and guiding future treatment strategies. The study is expected to conclude by the end of 2027, with the resulting data made accessible to approved researchers globally through the UK Biobank Research Analysis Platform.
Rapid ReadRapid Read
Gilead and Kite Announce New Data on Cancer and Autoimmune Disease Treatments at ASH 2026

Gilead and Kite Announce New Data on Cancer and Autoimmune Disease Treatments at ASH 2026

Gilead Sciences, Inc. and its company Kite have announced that they will present 23 new data presentations, including seven oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, scheduled from December 12–15, 2026. These presentations will highlight significant advancements across Gilead and Kite’s pipeline and portfolio, focusing on treatments for blood cancers and autoimmune disorders. Key data includes 18-month minimum follow-up results for anitocabtagene autoleucel (anito-cel) in relapsed or refractory multiple myeloma (RRMM) from the pivotal Phase 2 iMMagine-1 study. This data forms the basis of a Biologics License Application (BLA) currently under review by the U.S. Food and Drug Administration (FDA), with a target decision date of December 23, 2026. Additionally, five-year follow-up data for Yescarta® (axicabtagene ciloleucel) in first-line high-risk large B-cell lymphoma (LBCL) will be presented, along with early clinical results for KITE-753 in B-cell ...
TrendlineTrendline
Johnson Johnson Seeks Senior Director for Oncology Discovery, Emphasizing Computational Biology and AI

Johnson Johnson Seeks Senior Director for Oncology Discovery, Emphasizing Computational Biology and AI

Johnson Johnson Seeks Senior Director for Oncology Discovery, Emphasizing Computational Biology and AI
Rapid ReadRapid Read
Oncopeptides to Present New European Real-World Evidence for Pepaxti in Multiple Myeloma at ASH 2026

Oncopeptides to Present New European Real-World Evidence for Pepaxti in Multiple Myeloma at ASH 2026

Oncopeptides AB (publ), a biotech company specializing in difficult-to-treat cancers, has announced that two abstracts detailing real-world clinical outcomes for its drug Pepaxti (melflufen) in relapsed, refractory multiple myeloma (RRMM) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting. The meeting is scheduled to take place in New Orleans, USA, from December 12–15, 2026. These abstracts are based on two independent multicenter retrospective studies conducted in Spain and Italy, involving a total of 82 heavily pretreated RRMM patients. The studies aim to reinforce the clinical utility and manageable safety profile of Pepaxti when used in combination with dexamethasone in real-world European clinical practice. This includes its application in patients who have previously received T-cell-redirecting immunotherapies, such as anti-BCMA and anti-GPRC5D agents, and as a bridging therapy between immunotherapies.
Rapid ReadRapid Read
Pharmacogenomics Market Projected to Reach $15.98 Billion by 2030 Driven by AI and Precision Medicine

Pharmacogenomics Market Projected to Reach $15.98 Billion by 2030 Driven by AI and Precision Medicine

The pharmacogenomics market is experiencing rapid growth, with projections indicating it will reach $15.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.2%. This expansion is fueled by increasing investments in precision medicine, the growing adoption of AI-powered genomic analysis, and broader applications in oncology and cardiology. Key trends shaping the industry include personalized medicine adoption, genetic testing for drug selection, integration of pharmacogenomic data into clinical workflows, and the expansion of companion diagnostics. Major companies in this landscape include Illumina Inc, Eurofins Scientific, Myriad Genetics Inc, and Thermo Fisher Scientific Inc. Recent strategic moves, such as Genomenon's acquisition of Boston Genetics in June 2023, aim to enhance genomic intelligence capabilities by merging AI platforms with expert genome curation. Innovations like PGxAI's Sirius model, launched in December 2024, are further transforming drug response prediction and man...
Rapid ReadRapid Read
Merck and Moderna Demonstrate High Manufacturing Success for Personalized mRNA Cancer Vaccine in Phase 3 Trial

Merck and Moderna Demonstrate High Manufacturing Success for Personalized mRNA Cancer Vaccine in Phase 3 Trial

Merck and Moderna have reported significant success in the manufacturing and delivery of their personalized mRNA cancer vaccine, intismeran autogene, during the Phase 3 INTerpath-001 trial for high-risk melanoma. The companies successfully provided the custom-made vaccine to 99% of patients in the treatment arm, demonstrating the feasibility of deploying this complex, individualized therapy on a large scale. This achievement is crucial because these vaccines are custom-made for each patient using samples from their unique tumors obtained during resection. The manufacturing process involves sequencing patient tumor tissue to identify specific mutational signatures, then writing a personalized synthetic mRNA code for up to 34 neoantigens. This code instructs the immune system on how to combat the unique cancer. The trial, which included 1,137 patients with resected stage 2b to 4 melanoma, also showed that the vaccine, when paired with Merck’s Keytruda, reduced the risk of recurrence or death by 42%. The stud...
Rapid ReadRapid Read
Onchilles Pharma Reports Promising Early Clinical Data for N17350, a Personalized Cancer Vaccine Approach

Onchilles Pharma Reports Promising Early Clinical Data for N17350, a Personalized Cancer Vaccine Approach

Onchilles Pharma, a clinical-stage biotechnology company, has reported initial clinical findings from its Phase 1/2 trial (OP-NEU-101) of intratumoral N17350 in patients with advanced solid tumors. The data, presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), suggest that N17350 could effectively turn an injected tumor into a personalized cancer vaccine without requiring tumor sequencing or custom manufacturing. N17350 is an engineered therapeutic elastase derived from a cancer-killing enzyme found in human neutrophils. When injected into a tumor, it selectively kills cancer cells and releases the tumor's own antigens, thereby training the immune system to attack cancer elsewhere in the body. In the first dose cohort, three heavily pretreated patients showed no dose-limiting toxicities. Notably, a patient with Merkel cell carcinoma experienced the disappearance of five non-injected lesions after N17350 was injected into a single lesion, indicating systemic immune activat...
TrendlineTrendline
Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements

Zai Lab Reports Third Quarter 2026 Financial Results and Pipeline Advancements
Rapid ReadRapid Read
Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

Kamau Therapeutics Releases Encouraging Sickle Cell Clinical Data Ahead of ASH Meeting

Kamau Therapeutics, a California-based biotech company, has released preliminary clinical data for its gene-edited sickle cell disease (SCD) therapy, nula-cel. The data, to be presented at the American Society of Hematology (ASH) conference, show precise correction of the SCD mutation in the β-globin gene in three patients. These patients have also demonstrated restored expression of adult hemoglobin (HbA) and have become transfusion-independent, experiencing no pain crises since receiving their gene-edited hematopoietic stem cells (HSCs). Unlike FDA-approved Casgevy, which increases fetal hemoglobin (HbF), Kamau's nula-cel therapy directly replaces the SCD mutation using homology-directed repair (HDR). The company reports that sickle hemoglobin (HbS) levels fell below 20% of total hemoglobin in two patients who reached the 6-month post-infusion mark. The Phase I/II RESTORE trial is currently enrolling 15 participants.
TrendlineTrendline
Agenus Reports Strong Third Quarter 2026 Results and Advances Phase 3 ROBBIN Study for Colon Cancer

Agenus Reports Strong Third Quarter 2026 Results and Advances Phase 3 ROBBIN Study for Colon Cancer

Agenus Reports Strong Third Quarter 2026 Results and Advances Phase 3 ROBBIN Study for Colon Cancer
TrendlineTrendline
Roche Partners with Chai Discovery to Integrate AI for Protein Therapeutic Discovery

Roche Partners with Chai Discovery to Integrate AI for Protein Therapeutic Discovery

Roche Partners with Chai Discovery to Integrate AI for Protein Therapeutic Discovery
TrendlineTrendline
Mondego Bio Initiates First-in-Human Study of MB-388 for Cancer Immunotherapy Resistance

Mondego Bio Initiates First-in-Human Study of MB-388 for Cancer Immunotherapy Resistance

Mondego Bio Initiates First-in-Human Study of MB-388 for Cancer Immunotherapy Resistance